Arş. Gör. Mehmet Haluk YÜCEL

1. Association between malnutrition diagnosed by GLIM criteria and one-year mortality in hospitalized elderly patients: A prospective observational study

Yürüyen M., Geçmez G., Güven H. N. D., Deniz H., Yıldırım H. G., Yücel M. H., et al.

Nutrition in Clinical Practice , cilt.41, sa.3, ss.811-821, 2026 (SCI-Expanded, Scopus)

2. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

Sünger E., Muğlu H., Yücel M. H., Engin Delipoyraz E., Mıldanoğlu M. M., Özçelik H., et al.

Journal of clinical medicine , cilt.15, sa.8, 2026 (SCI-Expanded, Scopus)

3. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

Mıldanoğlu M. M., Kemik F., Eryaşar M., ÖZÇELİK H., SÜNGER E., Yücel M. H., et al.

Pharmaceuticals (Basel, Switzerland) , cilt.19, sa.4, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

MUĞLU H., HAMDARD J., KARAALİOĞLU B., SÜNGER E., Yücel M. H., Engi̇n Deli̇poyraz E., et al.

Journal of Oncological Science , cilt.12, sa.1, ss.103-110, 2026 (Scopus, TRDizin)

5. Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter Study

ÇETİNKAYA YAPRAK A., Yucel M. H., Karahan L., ERSOY M., BİLİCİ A., ERMAN M., et al.

Journal of Clinical Medicine , cilt.15, sa.8, 2026 (SCI-Expanded, Scopus)

6. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Mildanoglu M. M., Yucel M. H., Engin Delipoyraz E., SÜNGER E., ÖZÇELİK H., FİDAN S., et al.

Journal of clinical medicine , cilt.15, sa.6, 2026 (SCI-Expanded, Scopus)

7. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

Bayramgil A., Yücel M. H., Turkoglu E., Guren A. K., Kemik F., Ulufer B., et al.

Journal of Clinical Medicine , cilt.15, sa.6, 2026 (SCI-Expanded, Scopus)

8. Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study.

ERSOY M., KEFELİ U., ÇABUK D., BAYRAM E., Bayir D., BOZKURT O., et al.

Frontiers in immunology , cilt.17, ss.1714533, 2026 (SCI-Expanded, Scopus)

9. Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience

Hamdard J., Yücel M. H., Muğlu H., Açıkgöz Ö., Çakır A., Bilici A., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.9, ss.1-12, 2025 (SCI-Expanded, Scopus)

10. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: tek merkez deneyimi

Muglu H., Sünger E., YÜCEL M. H., Mildanoğlu M. M., Delipoyraz E. E., J., et al.

Ege Tıp Dergisi , cilt.64, sa.1, ss.71-76, 2025 (TRDizin)

11. SYNTHETIC CANNABINOID BONZAI RELATED CREATINE KINASE ENZYME ELEVATION: A TURKISH CENTER STUDY PORAST ENZIMA KREATIN KINAZE POVEZAN SA SINTETSKIM KANABINOIDOM BONZAI: ISTRAŽIVANJE CENTRA U TURSKOJ

Erismis B., Yilmaz D., Polat O., Deniz H., Yucel M. H., Hursitoglu M.

Acta Clinica Croatica , cilt.60, sa.3, ss.361-366, 2021 (SCI-Expanded, Scopus)

12. Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy

Akar E., Yücel M. H., Şahin T., Tural D.

Tumori , cilt.105, sa.6, 2019 (SCI-Expanded, Scopus)

13. Early effect of the fear of terrorism on a hospital's emergency department use and on the incidence of cardiovascular events: A Turkish multicenter study

Hursitoglu M., Erdal G. S., Akdeniz E., Kocoglu H., Kocamaz N., Tevetoglu I. O., et al.

International Journal of Health Planning and Management , cilt.34, sa.2, ss.872-879, 2019 (SSCI, Scopus)

Arş. Gör. Mehmet Haluk YÜCEL

Yayınlar & Eserler

1. Association between malnutrition diagnosed by GLIM criteria and one-year mortality in hospitalized elderly patients: A prospective observational study

2. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

3. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

4. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

5. Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter Study

6. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

7. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

8. Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study.

9. Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience

10. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: tek merkez deneyimi

11. SYNTHETIC CANNABINOID BONZAI RELATED CREATINE KINASE ENZYME ELEVATION: A TURKISH CENTER STUDY PORAST ENZIMA KREATIN KINAZE POVEZAN SA SINTETSKIM KANABINOIDOM BONZAI: ISTRAŽIVANJE CENTRA U TURSKOJ

12. Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy

13. Early effect of the fear of terrorism on a hospital's emergency department use and on the incidence of cardiovascular events: A Turkish multicenter study

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim